Free Trial
NASDAQ:TNGX

Tango Therapeutics Q4 2023 Earnings Report

Tango Therapeutics logo
$6.61 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$6.62 +0.01 (+0.15%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tango Therapeutics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Tango Therapeutics Revenue Results

Actual Revenue
$5.43 million
Expected Revenue
$7.86 million
Beat/Miss
Missed by -$2.43 million
YoY Revenue Growth
N/A

Tango Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 18, 2024
Conference Call Time
7:00AM ET

Tango Therapeutics Earnings Headlines

Wedbush Forecasts Stronger Earnings for Tango Therapeutics
Tango (TNGX) Q2 Revenue Drops 52%
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.
TNGX - Tango Therapeutics Inc News - Morningstar
See More Tango Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email.

About Tango Therapeutics

Tango Therapeutics (NASDAQ:TNGX), a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

View Tango Therapeutics Profile

More Earnings Resources from MarketBeat